Last month’s performance of 10.56% for Neurocrine Biosciences, Inc (NBIX) is certainly impressive

On Tuesday, Neurocrine Biosciences, Inc (NASDAQ: NBIX) opened higher 1.55% from the last session, before settling in for the closing price of $150.10. Price fluctuations for NBIX have ranged from $110.95 to $157.98 over the past 52 weeks.

A company in the Healthcare sector has jumped its sales by 24.80% annually for the last half of the decade. Company’s average yearly earnings per share was noted 58.81% at the time writing. With a float of $98.54 million, this company’s outstanding shares have now reached $101.20 million.

In an organization with 1400 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.0%, operating margin of 26.19%, and the pretax margin is 23.26%.

Neurocrine Biosciences, Inc (NBIX) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Neurocrine Biosciences, Inc is 2.68%, while institutional ownership is 91.33%. The most recent insider transaction that took place on Jan 31 ’25, was worth 266,025. In this transaction Chief Human Resources Officer of this company sold 1,740 shares at a rate of $152.89, taking the stock ownership to the 18,202 shares. Before that another transaction happened on Jan 31 ’25, when Company’s Director sold 2,707 for $152.92, making the entire transaction worth $413,967. This insider now owns 517,030 shares in total.

Neurocrine Biosciences, Inc (NBIX) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.67 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 58.81% per share during the next fiscal year.

Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators

Check out the current performance indicators for Neurocrine Biosciences, Inc (NBIX). In the past quarter, the stock posted a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.88. Likewise, its price to free cash flow for the trailing twelve months is 35.06.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.73, a number that is poised to hit 1.58 in the next quarter and is forecasted to reach 6.30 in one year’s time.

Technical Analysis of Neurocrine Biosciences, Inc (NBIX)

Let’s dig in a bit further. During the last 5-days, its volume was 0.87 million. That was inferior than the volume of 0.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 67.03%. Additionally, its Average True Range was 3.48.

During the past 100 days, Neurocrine Biosciences, Inc’s (NBIX) raw stochastic average was set at 94.98%, which indicates a significant increase from 86.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 16.06% in the past 14 days, which was lower than the 24.65% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $136.87, while its 200-day Moving Average is $133.69. However, in the short run, Neurocrine Biosciences, Inc’s stock first resistance to watch stands at $154.14. Second resistance stands at $155.86. The third major resistance level sits at $157.84. If the price goes on to break the first support level at $150.44, it is likely to go to the next support level at $148.46. The third support level lies at $146.74 if the price breaches the second support level.

Neurocrine Biosciences, Inc (NASDAQ: NBIX) Key Stats

There are currently 101,247K shares outstanding in the company with a market cap of 15.43 billion. Presently, the company’s annual sales total 1,887 M according to its annual income of 249,700 K. Last quarter, the company’s sales amounted to 622,100 K and its income totaled 129,800 K.